This study evaluated whether a nonproliferative tumor cell phenotype, P21 (CDKN1A inhibitor)-positive and MCM2 (DNA replication protein)-negative (P21+/MCM2-), could serve as a robust biomarker to improve prognostic stratification and guide postnephrectomy treatment decisions. This evidence concerns the gene MCM2 and neoplasm.